Table 4 Statements for which consensus was not achieved

1

Q4.

Recommendations (including technology-based and clinical measures) should fall within the ICF Framework.

25

1

Q16R.

Q16C.

Which categories – kinematic, kinetic, quality of movement, effort, and neuropsychological and other non-motor domain measures are most important for researchers and clinicians.

20 (R)

20 (C)

2

Q25R.

Q25C.

The amount of time researchers and clinicians would be willing to spend on using outcome measures for assessment (beginning and end of seeing patient).

14 (R)

14 (C)

2

Q26R.

Q26C.

The frequency researchers and clinicians would be willing to evaluate the patient’s progress.

17 (R)

17 (C)

2

Q27R.

Q27C.

The amount of time researchers and clinicians would be willing to spend on using outcome measures for evaluation of patient progress.

14 (R)

14 (C)

3

Q18C.

Which Quality of Movement Measures should be recommended for clinicians to use.

20

3

Q19C.

Which Muscle Activity Measures (EMG) should be recommended for clinicians to use.

17

3

Q20R.

Which Effort During Movement Measures should be recommended for researchers to use.

20

3

Q21C.

Which Neuropsychological and other non-motor domain measures should be recommended for clinicians to use.

14

3

Q29.

Which non-technology-based Measures of Impairment should be recommended.

20

3

Q13R.

In research, non-technology-based Measures of Activity should be restricted to validated outcome measures such as the Action Research Arm Test (ARAT) or Wolf Motor Function Test (WMFT).

20

3

Q30.

Which non-technology-based Measures of Activity should be recommended.

17

3

Q31.

Which non-technology-based Measures of Participation should be recommended.

25

3

Q22R.

Q22C.

Which categories of technology-based Measures of Participation should be recommended for researchers and clinicians to use.

20 (R)

20 (C)

3

Q24C.

Which Neurophysiology Measures should be recommended for clinicians to use.

20

4

Q33.

Which Self-Reported Measures should be recommended.

33

4

Q36R.

Q36C.

The minimum frequency of face-to-face patient assessment (other than data collected automatically by technology) for researchers and clinicians.

25 (R)

25 (C)

4

Q25R.

Q25C.

The amount of time researchers and clinicians are to spend in face-to-face assessment at the beginning and end of a treatment programme.

20 (R)

20 (C)

4

Q26R.

Q26C.

The amount of time researchers and clinicians are to spend in spend in face-to-face assessment of patients’ progress.

20 (R)

20 (C)